Dr. Allen is the a co-founder, of Clovis Oncology, a NASDAQ-listed cancer therapeutics company with a focus upon drug and companion diagnostic development. Diagnostic partnerships have included Ventana, Roche Molecular Systems and Foundation Medicine. Previously he was Chief Medical Officer and EVP at Pharmion Corp,.
Pharmion also secured the approval in Europe of thalidomide for the front-line treatment of multiple myeloma patients ineligible for transplant.
Prior to Pharmion, Dr. Allen was Vice President Oncology Drug Development at Chiron, one of the original biotechnology companies in the Bay Area, which was acquired by Novartis.
Previously, Dr. Allen served as global project head in Abbott Laboratories' oncology franchise, and prior to that he progressed through positions of increasing responsibility at McKinsey & Company, in the development and execution of business strategies for top-tier biotechnology and pharmaceutical companies, with a focus on oncology.
Dr. Allen qualified in Medicine at Oxford University and earned his Ph.D. from the Imperial College of Science, Technology and Medicine in London. Dr. Allen also obtained post-graduate internal medicine qualification as a Member of Royal College of Physicians (MRCP).